GlassScriptPhysician profile
David Vincent Spencer
NPI 1154820157
$8,997.99
in general payments reported to CMS, 2019-2025
52 companies · $875 in 2025
The $875 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,626 · 2020: $1,640 · 2021: $1,851 · 2022: $1,002 · 2023: $1,244 · 2024: $760 · 2025: $875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,878.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,347.74 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $1,148.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,010.12 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $781.87 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $506.93 | 2019-2023 | |
| Abbvie INC. | $286.65 | 2021-2025 | Vraylar |
| Amarin Pharma, INC. | $268.76 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $255.59 | 2019-2022 | |
| Grifols USA, LLC | $251.60 | 2019-2025 | Prolastin-C Liquid |
| Otsuka America Pharmaceutical, INC. | $210.21 | 2022-2025 | Rexulti, Abilify Maintena |
| Glaxosmithkline, LLC. | $207.25 | 2019-2022 | |
| Mylan Specialty L.P. | $204.79 | 2019-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $201.35 | 2022-2024 | |
| Abbott Laboratories | $188.84 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $188.14 | 2022-2025 | Caplyta |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Spencer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.